Literature DB >> 19260461

Outcome of surgical resection for hilar cholangiocarcinoma in elderly patients.

Tokihiko Sawada1, Junji Kita, Kyu Rokkaku, Masato Kato, Mitsugi Shimoda, Keiichi Kubota.   

Abstract

BACKGROUND/AIMS: The aim of the present study was to assess the safety and outcome of surgical resection for hilar cholangiocarcinoma in the elderly.
METHODOLOGY: Thirty-one patients with hilar cholangiocarcinoma were divided into two groups: Group 1 (n=8), less than 65, and; Group 2 (n=23), 65 years of age and older. Patient characteristics, peri-operative data, 5-year survival rates and 5-year disease-free survival rates were compared between the two groups.
RESULTS: There were no differences in patient characteristics except that the AST level at admission was higher in Group 2 than in Group 1. There were no differences in peri-operative data. Postoperative morbidity rates in Groups 1 and 2 were 12.5% and 33.3%, respectively (p=0.23). Median periods of postoperative hospitalization in Groups 1 and 2 were 32.5 days and 66 days, respectively (p=0.03). Overall 5-year survival rates in Groups 1 and 2 were 37.5% and 44.7%, respectively (p=0.57), and the respective 5-year disease-free survival rates were 25.0% and 28.6% (p= 0.37).
CONCLUSIONS: Although surgical resection for hilar cholangiocarcinoma in the elderly is associated with relatively high morbidity rate and longer hospital stay, it can be performed safely as in the younger, by employing accurate peri-operative management.

Entities:  

Mesh:

Year:  2008        PMID: 19260461

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  2 in total

1.  Loss of MTSS1 expression is an independent prognostic factor for Hilar cholangiocarcinoma.

Authors:  Fei Wang; Yulong Liu; Hao Zhang
Journal:  Pathol Oncol Res       Date:  2013-07-14       Impact factor: 3.201

2.  Patterns of care and treatment outcomes in older patients with biliary tract cancer.

Authors:  Anne Horgan; Jennifer Knox; Priya Aneja; Lisa Le; Elizabeth McKeever; Mairead McNamara
Journal:  Oncotarget       Date:  2015-12-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.